RYTM FY 2024 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$130M+68.1% YoY

Gross Profit

$117M89.7% margin

Operating Income

-$266M-204.0% margin

Net Income

-$261M-200.3% margin

EPS (Diluted)

$-4.34

Cash Flow

Operating Cash Flow

-$114M

Free Cash Flow

-$114M

Stock-Based Comp.

$40M

Balance Sheet

Total Assets

$392M

Total Liabilities

$228M

Stockholders' Equity

$165M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$130M	$77M	+68.1%
Gross Profit	$117M	$68M	+71.4%
Operating Income	-$266M	-$184M	-44.0%
Net Income	-$261M	-$185M	-41.1%